Drug profile · INN
treosulfan
TRECONDI
treosulfan (TRECONDI) is a dna cross-linking agent. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — treosulfan
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 6
- Data quality
- 0.84
Quick answer
treosulfan (TRECONDI) is a dna cross-linking agent. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
DNA cross-linking agent
Primary target: DNA
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is treosulfan?
treosulfan (TRECONDI) is a dna cross-linking agent. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for treosulfan?
TRECONDI is a marketed brand name for treosulfan. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of treosulfan?
treosulfan has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.